Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barclays at a price target of $48. Barclays sees ...

Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...

If you are wondering whether Hims & Hers Health is still a smart buy after its big run, you are not alone. This stock has quickly moved from a niche telehealth play to one of the market's more talked ...

Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical companies. Investors would do best to avoid ...

Hims & Hers Health Inc. (NYSE: HIMS) stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company’s valuation, ...

Hims & Hers shows platform expansion, verticalization, new Labs offerings, slower FCF growth and strong long-term revenue targets. Learn why HIMS stock is a buy.